Hellerup, Denmark, January 5, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CEO of UNION will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8-11, 2024, in San Francisco, US.
Dr. Kjøller will be presenting at 11:00am PST on Monday, January 8, 2024, and will provide an update on the business with emphasis on key achievements and current status of the lead program orismilast, a potent selective PDE4 B/D inhibitor, currently in development for atopic dermatitis, hidradenitis suppurativa, psoriasis and ulcerative colitis.
Contacts
Morten Boesen, Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S
+45 5385 3044
About UNION therapeutics
UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at http://www.uniontherapeutics.com
